Description:15% is today's daily digit in Europe. It's how much shares in Novo Nordisk initially tumbled on Monday morning, after US regulators demanded the drugmaker carry out more clinical tests of its insulin drug Tresiba, to assess potential heart risks. The Danish firm is the world's biggest insulin maker and it's been banking on Tresiba to help it remain the leader in diabetes care, ahead of rivals such as Sanofi.(0:58)